In vitro and in vivo antiangiogenic properties of the serpin protease nexin-1

Molecular and Cellular Biology

Volumn 32, Issue 8, 2012, Pages 1496-1505

  Selbonne, Sonia ^a   Azibani, Feriel ^a,c   Iatmanen, Soria ^a   Boulaftali, Yacine ^a,d   Richard, Benjamin ^a,b   Martine, Jandrot Perrus ^a   Bouton, Marie Christine ^a   Arocas, Véronique ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b National Institute for Health Surveillance   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; PROTEASE NEXIN I; PROTEOHEPARAN SULFATE; VASCULOTROPIN; VITRONECTIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; SERPIN E2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 84861321842     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06554-11     Document Type: Article

References (38)

1. Asanuma K, et al. 2007. Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity. Int. J. Cancer 121:955-965.
2. Baker JB, Low DA, Simmer RL, Cunningham DD. 1980. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21:37-45.
3. Balsara RD, Ploplis VA. 2008. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb. Haemost. 100:1029-1036.
4. Boulaftali Y, et al. 2010. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood 115:97-106.
5. Boulaftali Y, et al. 2011. Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis. Circulation 123:1326-1334.
6. Bouton MC, et al. 2003. The serpin protease-nexin 1 is present in rat aortic smooth muscle cells and is upregulated in L-NAME hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 23:142-147.
7. Bouton MC, et al. 2007. Protease nexin-1 interacts with thrombomodulin and modulates its anticoagulant effect. Circ. Res. 100:1174-1181.
8. Chen LM, Zhang X, Chai KX. 2004. Regulation of prostasin expression and function in the prostate. Prostate 59:1-12.
9. Eaton DL, Baker JB. 1983. Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmic serine proteasebinding factor. J. Cell Physiol. 117:175-182.
10. Feng W, et al. 2011. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 117:3893-3902.
11. Gerhardt H, et al. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161:1163-1177.
12. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. 1992. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267:6093-6098.
13. Gronke RS, Knauer DJ, Veeraraghavan S, Baker JB. 1989. A form of protease nexin I is expressed on the platelet surface during platelet activation. Blood 73:472-478.
14. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267:26031-26037.
15. Jang JH, Wang F, Kan M. 1997. Heparan sulfate is required for interaction and activation of the epithelial cell fibroblast growth factor receptor-2IIIb with stromal-derived fibroblast growth factor-7. In Vitro Cell Dev. Biol. Anim. 33:819-824.
16. Knauer DJ, Majumdar D, Fong PC, Knauer MF. 2000. SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor. J. Biol. Chem. 275:37340-37346.
17. Knauer MF, Kridel SJ, Hawley SB, Knauer DJ. 1997. The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins. J. Biol. Chem. 272:29039-29045.
18. Larsson H, et al. 2000. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 60:6723-6729.
19. Lee SY, et al. 2008. F2L, a peptide derived from heme-binding protein, inhibits LL-37-induced cell proliferation and tube formation in human umbilical vein endothelial cells. FEBS Lett. 582:273-278.
20. Li X, Herz J, Monard D. 2006. Activation of ERK signaling upon alternative protease nexin-1 internalization mediated by syndecan-1. J. Cell Biochem. 99:936-951.
21. Low DA, Baker JB, Koonce WC, Cunningham DD. 1981. Released protease-nexin regulates cellular binding, internalization, and degradation of serine proteases. Proc. Natl. Acad. Sci. U. S. A. 78:2340-2344.
22. Luthi A, et al. 1997. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J. Neurosci. 17:4688-4699.
23. Mansilla S, et al. 2008. Macrophages and platelets are the major source of protease nexin-1 in human atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 28:1844-1850.
24. Moestrup SK, Gliemann J, Pallesen G. 1992. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 269:375-382.
25. Monard D, Suidan HS, Nitsch C. 1992. Relevance of the balance between glia-derived nexin and thrombin following lesion in the nervous system. Ann. N. Y. Acad. Sci. 674:237-242.
26. Muhl L, et al. 2007. Inhibition of PDGF-BB by factor VII-activating protease (FSAP) is neutralized by protease nexin-1, and the FSAPinhibitor complexes are internalized via LRP. Biochem. J. 404:191-196.
27. Onuma Y, Asashima M, Whitman M. 2006. A serpin family gene, protease nexin-1 has an activity distinct from protease inhibition in early Xenopus embryos. Mech. Dev. 123:463-471.
28. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. 1999. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928.
29. Passaniti A, et al. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519-528.
30. Richard B, et al. 2004. Protease nexin-1: a cellular serpin down-regulated by thrombin in rat aortic smooth muscle cells. J. Cell Physiol. 201:138-145.
31. Richard B, et al. 2006. Modulation of protease nexin-1 activity by polysaccharides. Thromb. Haemost. 95:229-235.
32. Richard B, et al. 2006. The serpin protease nexin-1 regulates vascular smooth muscle cell adhesion, spreading, migration and response to thrombin. J. Thromb. Haemost. 4:322-328.
33. Rossignol P, et al. 2004. Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J. Biol. Chem. 279:10346-10356.
34. Stone SR, et al. 1994. Localization of the heparin-binding site of gliaderived nexin/protease nexin-1 by site-directed mutagenesis. Biochemistry 33:7731-7735.
35. Stringer SE. 2006. The role of heparan sulphate proteoglycans in angiogenesis. Biochem. Soc. Trans. 34:451-453.
36. Wallace A, Rovelli G, Hofsteenge J, Stone SR. 1989. Effect of heparin on the glia-derived nexin-thrombin interaction. Biochem. J. 257:191-196.
37. Zhang W, et al. 2005. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 106:1621-1628.
38. Zhang W, Swanson R, Xiong Y, Richard B, Olson ST. 2006. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J. Biol. Chem. 281: 37302-37310.